Magenta therapeutics, inc. (MGTA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-81,946

-76,769

-70,211

-65,236

-61,188

-57,515

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

10,164

10,001

10,490

11,404

11,855

10,703

0

0

0

Depreciation and amortization expense

1,913

1,843

1,717

1,443

1,151

875

0

0

0

Net amortization (accretion) of premiums (discounts) on marketable securities

683

1,009

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-5,044

1,363

1,635

8,408

6,770

1,811

0

0

0

Accounts payable

1,938

145

-233

1,075

636

2,500

0

0

0

Accrued expenses and other current liabilities

4,178

5,089

1,876

2,170

1,764

2,239

0

0

0

Deferred rent

-568

-4,960

0

0

0

-

-

-

-

Net cash used in operating activities

-58,824

-57,103

-54,100

-53,142

-47,218

-41,886

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

1,940

3,060

7,258

9,203

8,762

7,672

0

0

0

Purchases of marketable securities

130,365

144,371

0

0

0

-

-

-

-

Maturities of marketable securities

171,963

148,963

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

39,658

1,532

-81,139

-147,422

-104,273

-91,703

0

0

0

Cash flows from financing activities:
Payments of public offering costs

-

-

-

-

-

3,094

0

0

0

Payments of redeemable convertible preferred stock issuance costs

-

-

-

-

-

88

0

0

0

Proceeds from exercise of common stock options

2,582

2,021

0

0

0

-

-

-

-

Net cash provided by financing activities

62,858

62,297

60,907

60,081

142,885

142,147

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

43,692

6,726

-74,332

-140,483

-8,606

8,558

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable and accrued expenses

0

-

-

1,579

2,591

1,538

0

0

0

Deferred offering and redeemable convertible preferred share issuance costs included in accounts payable or accrued expenses

0

-

-

-

0

-

-

-

-

Deferred offering and redeemable convertible preferred share issuance costs included in accounts payable and accrued expenses

0

-

-

0

0

-

-

0

0